Loading...
•
Mar 31, 2025
Puma Biotechnology Q1 2025 Earnings Report
Puma Biotechnology Reports First Quarter Financial Results
Key Takeaways
Puma Biotechnology reported a net income of $3.0 million for the first quarter of 2025, a significant improvement compared to a net loss in the same period last year. Total revenue increased to $46.0 million, driven by higher net product revenue from NERLYNX.
Net income for Q1 2025 was $3.0 million, compared to a net loss of $4.8 million in Q1 2024.
Total revenue for Q1 2025 was $46.0 million, an increase from $43.8 million in Q1 2024.
Net product revenue from NERLYNX increased to $43.1 million in Q1 2025 from $40.3 million in Q1 2024.
Non-GAAP adjusted net income was $5.0 million in Q1 2025, up from a non-GAAP adjusted net loss of $2.4 million in Q1 2024.
Revenue by Segment
Forward Guidance
Puma Biotechnology provided financial guidance for the second quarter and full year 2025, expecting continued revenue from NERLYNX and royalty revenue, and anticipates net income for both periods.
Positive Outlook
- Anticipates net product revenue between $48 million and $50 million for Q2 2025.
- Projects full year 2025 net product revenue between $192 million and $198 million.
- Forecasts royalty revenue between $2 million and $3 million for Q2 2025.
- Estimates full year 2025 royalty revenue between $20 million and $24 million.
- Expects net income between $4 million and $6 million for Q2 2025.
Challenges Ahead
- No license revenue is anticipated for Q2 2025 or the full year 2025.
- The outlook does not include any adjustments for tax valuation allowance.
- Gross to net adjustment is expected to be between 20% and 21.5% for Q2 and full year 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...